Stock listing
Lang & Schwarz:A2PF3G CorMedix Inc. Aktie
German listing (Lang & Schwarz) of CorMedix Inc. · home listing NASDAQ:CRMD
Follow CorMedix Inc. into a list and get an email when it puts out news.
Home listing price · NASDAQ:CRMD
$5.27 USD +0.77 (+17.1%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:CRMD
- Day range
- $4.95 – $5.32 USDNov 20, 2026
- Volume
- 3.61M sharesNov 20, 2026
- Market cap
- $410.8M USDAt the close on Nov 20, 2026 · price × 77.94M shares outstanding
- 52-week range
- $4.49 – $13.02 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $9.34M USDMedian day 1.09M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:CRMD · Home | $5.27 USD | +0.77 (+17.1%) | 3,608,270 | $4.96 | $5.315 | $4.95 | $4.50 | Close on Nov 20, 2026 |
| Frankfurt:19KA | €4.659 EUR | +0.426 (+10.1%) | — | €4.415 | €4.659 | €4.415 | €4.233 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CRMD · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $5.27 | +0.77 | +17.1% | $4.96 | $5.315 | $4.95 | 3,608,270 | |
| $4.50 | -0.17 | -3.6% | $4.65 | $4.71 | $4.485 | 1,589,502 | |
| $4.67 | -0.15 | -3.1% | $4.79 | $4.87 | $4.635 | 1,987,052 | |
| $4.82 | +0.16 | +3.4% | $5.05 | $5.233 | $4.75 | 3,195,451 | |
| $4.66 | -0.18 | -3.7% | $4.88 | $5.055 | $4.65 | 2,391,229 | |
| $4.84 | -0.46 | -8.7% | $5.15 | $5.49 | $4.815 | 3,675,346 | |
| $5.30 | -0.07 | -1.3% | $5.33 | $5.42 | $5.24 | 1,618,545 | |
| $5.37 | -0.10 | -1.8% | $5.49 | $5.67 | $5.29 | 2,341,388 | |
| $5.47 | +0.15 | +2.8% | $5.47 | $5.56 | $5.16 | 2,325,920 | |
| $5.32 | +0.09 | +1.7% | $5.25 | $5.34 | $5.10 | 1,616,500 | |
| $5.23 | -0.43 | -7.6% | $5.75 | $5.77 | $5.21 | 1,829,300 | |
| $5.66 | +0.10 | +1.8% | $5.71 | $5.79 | $5.58 | 1,491,200 | |
| $5.56 | +0.17 | +3.2% | $5.35 | $5.60 | $5.30 | 2,456,900 | |
| $5.39 | -0.31 | -5.4% | $5.70 | $5.75 | $5.34 | 3,303,800 | |
| $5.70 | -1.94 | -25.4% | $7.68 | $7.68 | $5.63 | 7,014,600 | |
| $7.64 | -0.56 | -6.8% | $8.34 | $8.35 | $7.46 | 1,886,200 | |
| $8.20 | +0.20 | +2.5% | $7.95 | $8.22 | $7.90 | 1,156,800 | |
| $8.00 | +0.06 | +0.8% | $7.91 | $8.11 | $7.80 | 1,002,300 | |
| $7.94 | +0.09 | +1.1% | $8.06 | $8.09 | $7.76 | 1,130,300 | |
| $7.85 | -0.25 | -3.1% | $8.01 | $8.11 | $7.79 | 894,300 | |
| $8.10 | +0.31 | +4.0% | $7.86 | $8.12 | $7.76 | 1,092,000 | |
| $7.79 | +0.22 | +2.9% | $7.55 | $7.85 | $7.51 | 1,049,200 | |
| $7.57 | +0.19 | +2.6% | $7.38 | $7.61 | $7.38 | 971,100 | |
| $7.38 | +0.12 | +1.7% | $7.26 | $7.57 | $7.25 | 1,471,900 | |
| $7.26 | -0.20 | -2.7% | $7.47 | $7.47 | $7.24 | 1,140,400 | |
| $7.46 | +0.07 | +0.9% | $7.49 | $7.70 | $7.43 | 1,466,200 | |
| $7.39 | 0.00 | 0.0% | $7.36 | $7.53 | $7.27 | 1,124,900 | |
| $7.39 | -0.07 | -0.9% | $7.43 | $7.55 | $7.33 | 1,415,700 | |
| $7.46 | +0.08 | +1.1% | $7.41 | $7.60 | $7.16 | 1,592,000 | |
| $7.38 | +0.06 | +0.8% | $7.32 | $7.46 | $7.26 | 1,194,400 | |
| $7.32 | +0.04 | +0.5% | $7.28 | $7.36 | $7.18 | 1,018,300 | |
| $7.28 | 0.00 | 0.0% | $7.27 | $7.31 | $7.18 | 833,000 | |
| $7.28 | +0.02 | +0.3% | $7.38 | $7.40 | $7.13 | 744,300 | |
| $7.26 | +0.07 | +1.0% | $7.18 | $7.33 | $7.06 | 1,256,000 | |
| $7.19 | -0.23 | -3.1% | $7.45 | $7.45 | $7.17 | 1,125,200 | |
| $7.42 | -0.28 | -3.6% | $7.65 | $7.69 | $7.40 | 1,051,100 | |
| $7.70 | -0.23 | -2.9% | $7.95 | $7.95 | $7.66 | 948,400 | |
| $7.93 | +0.04 | +0.5% | $7.91 | $7.96 | $7.82 | 817,400 | |
| $7.89 | +0.04 | +0.5% | $7.77 | $7.90 | $7.77 | 485,000 | |
| $7.85 | +0.08 | +1.0% | $7.79 | $7.90 | $7.69 | 606,600 | |
| $7.77 | +0.08 | +1.0% | $7.70 | $7.79 | $7.62 | 946,500 | |
| $7.69 | -0.09 | -1.2% | $8.03 | $8.19 | $7.63 | 812,400 | |
| $7.78 | +0.01 | +0.1% | $7.83 | $7.83 | $7.69 | 788,900 | |
| $7.77 | +0.05 | +0.6% | $7.72 | $7.82 | $7.62 | 505,700 | |
| $7.72 | -0.07 | -0.9% | $7.65 | $7.79 | $7.62 | 1,806,500 | |
| $7.79 | -0.03 | -0.4% | $7.86 | $7.92 | $7.70 | 684,700 | |
| $7.82 | +0.06 | +0.8% | $7.78 | $7.87 | $7.72 | 664,400 | |
| $7.76 | -0.13 | -1.6% | $7.90 | $7.90 | $7.71 | 717,700 | |
| $7.89 | +0.06 | +0.8% | $7.83 | $7.95 | $7.75 | 920,200 | |
| $7.83 | -0.13 | -1.6% | $8.04 | $8.06 | $7.82 | 820,500 | |
| $7.96 | -0.17 | -2.1% | $8.11 | $8.12 | $7.92 | 857,300 | |
| $8.13 | -0.05 | -0.6% | $8.18 | $8.33 | $8.08 | 928,200 | |
| $8.18 | -0.25 | -3.0% | $8.28 | $8.37 | $8.11 | 1,101,000 | |
| $8.43 | -0.04 | -0.5% | $8.45 | $8.61 | $8.31 | 792,800 | |
| $8.47 | -0.14 | -1.6% | $8.69 | $8.75 | $8.43 | 706,700 | |
| $8.61 | +0.23 | +2.7% | $8.40 | $8.62 | $8.33 | 1,102,000 | |
| $8.38 | +0.12 | +1.5% | $8.25 | $8.49 | $8.18 | 880,400 | |
| $8.26 | -0.04 | -0.5% | $8.26 | $8.29 | $8.06 | 980,500 | |
| $8.30 | -0.01 | -0.1% | $8.28 | $8.40 | $8.19 | 775,800 | |
| $8.31 | -0.08 | -1.0% | $8.49 | $8.49 | $8.28 | 703,900 | |
| $8.39 | -0.17 | -2.0% | $8.60 | $8.61 | $8.37 | 865,400 | |
| $8.56 | +0.28 | +3.4% | $8.35 | $8.575 | $8.28 | 1,235,615 | |
| $8.28 | +0.08 | +1.0% | $8.28 | $8.495 | $8.18 | 1,012,332 | |
| $8.20 | -0.03 | -0.4% | $8.29 | $8.41 | $8.16 | 1,496,600 | |
| $8.23 | -0.29 | -3.4% | $8.49 | $8.54 | $8.19 | 1,006,400 |
Splits
1 split · NASDAQ:CRMD · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-5 | Consolidation |
- Ticker
- Lang & Schwarz:A2PF3G
- Asset type
- Stock
- Sector
- Health care
- Industry
- Pharmaceuticals
- Exchange
- Lang & Schwarz
- Currency
- EUR
What changed lately
Latest news release · Nov 12, 2026
Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Latest earnings call · Nov 12, 2026
CorMedix (NASDAQ:CRMD) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 10, 2026
Merger or Acquisition (November 2026)
Merger or acquisition · 7 slides
Latest news
Cormedix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 12, 2026
Closed $4.84 (-8.7%) on Nov 12, 2026
CorMedix Therapeutics to Acquire Substantially All Assets of Heron Therapeutics, Expanding Its Portfolio of Products Used in Institutional Settings of Care
Nov 9, 2026
Closed $5.47 (+2.8%) on Nov 9, 2026
CorMedix Therapeutics to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
Nov 6, 2026
Closed $5.32 (+1.7%) on Nov 6, 2026
CorMedix Therapeutics Provides Business Update, Reaffirms 2026 Total Revenue Guidance, and Reports Third Quarter Cash Position
Nov 2, 2026
Closed $5.39 (-5.4%) on Nov 2, 2026
Cormedix Announces FDA Acceptance for Priority Review of Supplemental NDA for Rezzayo® (Rezafungin) for Prophylaxis of Invasive Fungal Diseases
Oct 19, 2026
Closed $7.38 (+1.7%) on Oct 19, 2026
CorMedix Therapeutics to Participate in the Wells Fargo Healthcare Conference
Sep 1, 2026
Closed $8.38 (+1.5%) on Sep 1, 2026
Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 13, 2026
Closed $8.14 (+14.6%) on Aug 13, 2026
CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026
Jul 29, 2026
Closed $7.19 (-2.2%) on Jul 29, 2026
U.S. Court of Appeals for the Federal Circuit Affirms Victory for Cormedix Therapeutics in Minocin® Patent Litigation
Jun 8, 2026
Closed $8.54 (+2.2%) on Jun 8, 2026
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
May 15, 2026
Closed $7.55 (-4.8%) on May 15, 2026
CorMedix Inc. on 6ix
- Sector
- Health care
- Industry
- Pharmaceuticals
- News releases
- 22 in the last 12 months · 170 in all · newest Nov 12, 2026 · oldest 2019
- Calls
- 26 calls with a replay · 26 with a transcript · latest Nov 12, 2026
- Decks
- 34 decks · latest Nov 10, 2026
Where CorMedix Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:CRMD · Home listing | NASDAQ | United States | USD |
| gettex:19KA | gettex | Germany | EUR |
| Tradegate:19KA | Tradegate | Germany | EUR |
| Stuttgart:19KA | Stuttgart | Germany | EUR |
| LS Exchange:A2PF3G | LS Exchange | Germany | EUR |
| BOATS:CRMD | BOATS | United States | USD |
| Lang & Schwarz:A2PF3G · This page | Lang & Schwarz | Germany | EUR |
| Frankfurt:19KA | Frankfurt | Germany | EUR |
| Munich:19KA | Munich | Germany | EUR |
| Dusseldorf:19KA | Dusseldorf | Germany | EUR |
| Hamburg:19KA | Hamburg | Germany | EUR |
Valuation
P/E 6.4× against a median of 35.7×: the lowest of 8 Pharmaceuticals companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $201.0M USD
- P/E
- 6.4×
- EV/sales
- 0.5×
- EV/EBITDA
- 1.0×
- Price/book
- 0.9×
- Gross margin
- 77.5%
- Operating margin
- 38.6%
- Net margin
- 15.5%
- Debt to equity
- 0.3×
- Beta vs S&P 500
- 0.71
Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| CorMedix Inc. · NASDAQ:CRMD | US$410.8M | US$201.0M | 6.4× | 0.5× | 1.0× | 0.9× | 15.5% | 0.3× | 0.71 |
| Zhejiang Chengyi Pharmaceutical Co. Ltd. Class A · SSE:603811 | US$426.4M | US$399.3M | 15.0× | 3.2× | n/a | 1.9× | 22.8% | 0.0× | n/a |
| Harbin Medisan Pharmaceutical Co., Ltd. Class A · SZSE:002900 | US$413.1M | US$377.4M | n/a | 3.0× | n/a | 1.6× | −27.1% | 0.1× | n/a |
| PKU Healthcare Corp. Ltd. Class A · SZSE:000788 | US$412.4M | US$243.9M | 133× | 1.8× | n/a | 1.8× | 2.3% | 0.0× | n/a |
| Huaren Pharmaceutical Co., Ltd. Class A · SZSE:300110 | US$409.9M | US$445.4M | n/a | 2.4× | n/a | 3.2× | −40.2% | 0.5× | n/a |
| Handa Pharmaceuticals Inc · TPEX:6620 | US$405.8M | US$292.6M | 27.3× | 8.0× | 15.6× | 2.7× | 40.5% | 0.0× | n/a |
| ScinoPharm Taiwan, Ltd. · TWSE:1789 | US$404.2M | US$324.5M | 797× | 3.5× | n/a | 1.3× | 0.5% | 0.1× | n/a |
| Zhuhai Rundu Pharmaceutical Co. Ltd. Class A · SZSE:002923 | US$401.6M | US$381.7M | 47.1× | 1.9× | n/a | 2.4× | 4.2% | 0.2× | n/a |
| Cheng Du Sheng Nuo Biotec Co., Ltd. Class A · SSE:688117 | US$398.5M | US$406.8M | 12.7× | 2.8× | n/a | 2.3× | 21.8% | 0.3× | n/a |
| Kexing Biopharm Co., Ltd. Class A · SSE:688136 | US$398.1M | US$410.5M | 35.7× | 2.1× | n/a | 1.5× | 5.7% | 0.4× | n/a |
| Shaanxi Kanghui Pharmaceutical Co. , Ltd. Class A · SSE:603139 | US$393.1M | US$396.8M | n/a | 5.1× | n/a | 3.9× | −38.4% | 0.2× | n/a |
| Median of the others | US$405.0M | US$389.3M | 35.7× | 2.9× | 15.6× | 2.1× | 3.2% | 0.2× |
Forecasts
3 strong buy · 3 buy · Analysts' consensus from EODHD, read Nov 14, 2026. Not 6ix's view and not investment advice.
- Price target
- 14.83 USD · Analysts' mean
- EPS, year to Dec 2026
- 0.49 · 1 analyst
- Revenue, year to Dec 2026
- 336.8M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Joe Todisco | Chief Executive Officer and Chairman |
| Susan Blum | EVP & Chief Financial Officer |
| Liz Hurlburt | EVP, Chief Operating & Commercial Officer |
| Beth Zelnick Kaufman | EVP, Chief Legal and Compliance Officer, and Corporate Secretary |
| Mike Seckler | EVP & Chief Commercial Officer |
Board
| Director | Role |
|---|---|
| Joe Todisco | Chief Executive Officer and Chairman |
| Alan W. Dunton | Director |
| Greg Duncan | Director |
| Janet D. Dillione | Director |
| Myron Kaplan | Lead Independent Director |
| Robert Stewart | Director |
| Steven Lefkowitz | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| CorMedix (NASDAQ:CRMD) Q3 2026 Earnings Call | Thu, Nov 12, 2026 · 8:30 AM ET | Replay |
| CorMedix (NASDAQ:CRMD) Q2 2026 Earnings Call | Thu, Aug 13, 2026 · 8:30 AM ET | Replay |
| CorMedix (NASDAQ:CRMD) Q1 2026 Earnings Call | Thu, May 14, 2026 · 8:30 AM ET | Replay |
| CorMedix (NASDAQ:CRMD) Q4 2025 Earnings Call | Thu, Mar 05, 2026 · 8:30 AM ET | Replay |
| CorMedix (NASDAQ:CRMD) Q3 2025 Earnings Call | Wed, Nov 12, 2025 · 8:30 AM ET | Replay |
| CorMedix (NASDAQ:CRMD) Q2 2025 Earnings Call | Thu, Aug 07, 2025 · 8:30 AM ET | Replay |
| CorMedix (NASDAQ:CRMD) Q1 2025 Earnings Call | Tue, May 06, 2025 · 8:30 AM ET | Replay |
| CorMedix (NASDAQ:CRMD) Q3 2024 Earnings Call | Wed, Oct 30, 2024 · 8:30 AM ET | Replay |
| CorMedix (NASDAQ:CRMD) Q2 2024 Earnings Call | Wed, Aug 14, 2024 · 8:30 AM ET | Replay |
| CorMedix (NASDAQ:CRMD) Q1 2024 Earnings Call | Thu, May 09, 2024 · 8:30 AM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 12, 2026 · Before open | −8.7% |
| Q2 2026 | Aug 13, 2026 · Before open | +14.7% |
| Q1 2026 | May 14, 2026 · Before open | +5.7% |
| Q4 2025 | Mar 31, 2026 | +6.8% |
| Q3 2025 | Nov 12, 2025 · Before open | +2.1% |
| Q2 2025 | Aug 7, 2025 · Before open | −9.5% |
| Q1 2025 | May 6, 2025 · Before open | +23.6% |
| Q4 2024 | Mar 10, 2025 · Before open | +0.2% |
| Q3 2024 | Oct 30, 2024 · Before open | −22.5% |
| Q2 2024 | Aug 14, 2024 · Before open | +30.2% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 · Before open | −5.2% |
| Q4 2023 | Mar 12, 2024 · Before open | −2.8% |
| Q3 2023 | Nov 14, 2023 · After close | +6.4% |
| Q2 2023 | Aug 8, 2023 · Before open | +7.9% |
| Q1 2023 | May 15, 2023 · After close | −13.4% |
| Q4 2022 | Mar 30, 2023 · Before open | +13.1% |
| Q3 2022 | Nov 10, 2022 · Before open | +9.2% |
| Q2 2022 | Aug 11, 2022 · Before open | +10.1% |
| Q1 2022 | May 12, 2022 · After close | +9.7% |
| Q4 2021 | Mar 29, 2022 · After close | +5.6% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (November 2026) | Merger or acquisition | 7 slides | Nov 10, 2026 |
| Merger or Acquisition (November 2026) | Merger or acquisition | 7 slides | Nov 9, 2026 |
| Technical Presentation (October 2026) | Technical | 16 slides | October 2026 |
| CorMedix Therapeutics — Investor Presentation (September 2026) | Investor deck | 25 slides | September 2026 |
| CorMedix Therapeutics — Investor Presentation (May 2026) | Investor deck | 24 slides | May 2026 |
| Investor Presentation (March 2026) | Investor deck | 23 slides | Mar 6, 2026 |
| CorMedix Therapeutics — Investor Day (February 2026) | Investor day | 50 slides | Feb 10, 2026 |
| CorMedix Therapeutics — J.P. Morgan Healthcare Conference 2026 | Conference | 23 slides | January 2026 |
| Investor Presentation (September 2025) | Investor deck | 19 slides | September 2025 |
| Q2 2025 Earnings Presentation | Earnings | 8 slides | Aug 7, 2025 |
All 34 decks
Financings
| Raise | Date |
|---|---|
| Convertible debt Closed: US$150M raised Buyers: Deerfield Use of proceeds: Funding the cash consideration for the acquisition of Melinta Therapeutics | Sep 2, 2025 |
| Public offering of shares of common stock Update: about US$85M · RBC Capital Markets +3 Dealers: RBC Capital Markets (lead), Truist Securities, Citizens Capital Markets, Needham & Company Use of proceeds: General corporate purposes, including working capital, research and product candidate development, and potential strategic transactions | Jun 27, 2025 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 311.7M | 43.5M | 0 | 65.4K | 190.9K | 239.2K | 283.3K | 429.8K | 329.3K | 224.1K |
| Cost of revenue | 22.1M | 3.03M | 205.6K | 3.73K | 148.9K | 204.8K | 373.2K | 396.8K | 115.0K | 366.7K |
| Gross profit | 275.7M | 40.3M | -205.6K | 61.7K | 42.0K | 34.4K | -90.0K | 33.0K | 214.4K | -142.6K |
| Research and development | 19.3M | 3.94M | 13.2M | 10.7M | 13.1M | 13.4M | 11.1M | 18.8M | 24.5M | 15.7M |
| Selling, general and administrative | 68.2M | 30.0M | 35.8M | 20.0M | 16.3M | 13.9M | 9.87M | 8.07M | 8.65M | 8.88M |
| Operating income | 150.1M | -22.4M | -49.0M | -30.6M | -29.4M | -27.2M | -21.0M | -26.9M | -32.9M | -24.8M |
| Depreciation and amortization | 677.0K | 154.0K | 70.8K | 84.6K | 61.9K | 128.0K | 73.3K | 74.2K | 36.9K | 25.6K |
| EBITDA | 150.8M | -22.2M | -48.9M | -30.5M | -29.4M | -27.1M | -20.9M | -26.8M | -32.9M | -24.7M |
| Interest expense | 2.78M | 36.0K | 34.3K | 26.5K | 15.9K | 33.2K | 787.5K | 1.87K | 5.62K | 1.31K |
| Income before tax | 150.0M | -19.3M | -46.3M | -30.3M | -29.5M | -27.2M | -21.5M | -26.8M | -33.0M | -24.6M |
| Income tax | -13.0M | -1.40M | -2 | -585.6K | -1.25M | -5.17M | -5.06M | 36.4K | -31.3K | 1.31K |
| Net income | 163.1M | -17.9M | -46.3M | -29.7M | -28.2M | -22.0M | -16.4M | -26.8M | -33.0M | -24.6M |
| Earnings per share, basic | 2.25 | -0.30 | -0.91 | -0.74 | -0.75 | -0.77 | -1.80 | -1.51 | -0.60 | -0.65 |
| Earnings per share, diluted | 2.04 | -0.30 | -0.91 | -0.74 | -0.75 | -0.77 | -1.80 | -1.51 | -0.60 | -0.65 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 144.8M | 40.7M | 43.6M | 43.1M | 53.3M | 41.9M | 16.4M | 17.6M | 10.4M | 8.06M |
| Short-term investments | 3.69M | 11.0M | 32.4M | 15.6M | 12.1M | 4.44M | 12.0M | 0 | 1.60M | 12.1M |
| Receivables | 171.2M | 51.7M | 0 | 0 | 45.4K | 3.36K | 35 | 10.9K | 64.1K | 12.0K |
| Inventory | 29.7M | 7.60M | 2.11M | 0 | 3.01K | 143.6K | 338.5K | 428.5K | 594.2K | 166.7K |
| Current assets | 367.1M | 114.6M | 79.5M | 59.6M | 66.5M | 48.2M | 29.3M | 18.7M | 13.3M | 21.8M |
| Property, plant and equipment | 5.96M | 1.83M | 1.87M | 1.61M | 1.47M | 111.5K | 122.1K | 160.9K | 186.3K | 69.7K |
| Goodwill | 30.0M | 1.84B | 0 | 0 | ||||||
| Total assets | 826.1M | 118.8M | 82.1M | 62.0M | 68.9M | 49.3M | 29.5M | 18.8M | 13.5M | 21.9M |
| Accounts payable | 7.88M | 1.72M | 4.28M | 2.20M | 2.21M | 1.13M | 1.02M | 2.59M | 1.81M | 1.65M |
| Current liabilities | 174.3M | 33.8M | 11.4M | 6.31M | 5.35M | 4.16M | 5.83M | 7.77M | 6.26M | 4.09M |
| Long-term debt | 144.6M | 6.13M | 0 | 0 | ||||||
| Total debt | 148.9M | 517.0K | 667.6K | 802.4K | 923.8K | 1.03M | 4.69K | 6.13M | ||
| Total liabilities | 420.8M | 34.2M | 11.9M | 6.98M | 6.15M | 5.09M | 5.83M | 13.9M | 6.26M | 4.09M |
| Shareholders' equity | 405.3M | 84.7M | 70.1M | 55.1M | 62.8M | 44.2M | 23.6M | 4.93M | 7.19M | 17.8M |
| Shares outstanding | 79.3M | 64.4M | 54.9M | 42.8M | 38.1M | 33.6M | 25.7M | 21.8M | 71.4M | 40.4M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 175.0M | -50.6M | -38.4M | -24.4M | -21.2M | -22.0M | -15.1M | -23.7M | -28.6M | -22.3M |
| Capital spending | -2.26M | -116.0K | -327.3K | -219.4K | -1.43M | -112.6K | -36.6K | -48.9K | -152.0K | -58.7K |
| Free cash flow | 172.8M | -50.7M | -38.7M | -24.6M | -22.6M | -22.1M | -15.1M | -23.7M | -28.7M | -22.3M |
| Cash from investing | -308.4M | 21.2M | -17.1M | -3.71M | -9.13M | 7.43M | -12.0M | 1.56M | 10.4M | 11.4M |
| Cash from financing | 238.5M | 26.3M | 55.9M | 17.9M | 41.8M | 40.1M | 25.8M | 29.4M | 20.5M | 7.09M |
| Dividends paid | 0 | 0 | ||||||||
| Share buybacks | -198.4K | 41.8M | 40.1M | 26.0M | 22.0M | 20.5M | 7.09M | |||
| Change in cash | 105.1M | -3.07M | 448.4K | -10.2M | 11.5M | 25.6M | -1.27M | 7.24M | 2.32M | -3.75M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| DFAN14A | Nov 13, 2026 | Other filings | SEC |
| DEFA14A · Additional proxy material | Nov 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | Nov 13, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Nov 10, 2026 | Meeting notice | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 8-K · Current report | Nov 10, 2026 | Current report | SEC |
| DEFA14A · Additional proxy material | Nov 9, 2026 | Meeting notice | SEC |
| 8-K · Current report | Nov 9, 2026 | Material contract | SEC |
| 8-K · Current report | Nov 2, 2026 | Results | SEC |
| 8-K · Current report | Oct 19, 2026 | Current report | SEC |
| 4 · Change in ownership | Sep 18, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 1, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 13, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2026 | Results | SEC |
| 8-K · Current report | Aug 7, 2026 | Current report | SEC |
| 8-K · Current report | Jul 2, 2026 | Current report | SEC |
| 8-K · Current report | Jul 1, 2026 | Current report | SEC |
| S-8 POS | Jun 25, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 24, 2026 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jun 12, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 8, 2026 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 14, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 14, 2026 | Results | SEC |
| ARS · Annual report to shareholders | Apr 29, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2026 | Meeting notice | SEC |
| 8-K · Current report | Apr 27, 2026 | Current report | SEC |
| PRE 14A · Preliminary proxy statement | Apr 17, 2026 | Meeting notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Mar 6, 2026 | Current report | SEC |
| 10-K · Annual report | Mar 5, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2026 | Results | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 27, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 20, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jan 15, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 8, 2026 | Results | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 2, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 2, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Dec 30, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 19, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 18, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 10, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 9, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 4, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Dec 1, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Nov 26, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 24, 2025 | Other filings | SEC |
| 4 · Change in ownership | Nov 18, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 14, 2025 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Nov 13, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 144 · Notice of proposed sale | Nov 10, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 6, 2025 | Other filings | SEC |
| 4 · Change in ownership | Oct 27, 2025 | Insider trade | SEC |
| DEF 14A · Proxy statement | Oct 24, 2025 | Meeting notice | SEC |
| 8-K · Current report | Oct 20, 2025 | Results | SEC |
| PRER14A | Oct 14, 2025 | Other filings | SEC |
| S-3ASR · Registration statement | Oct 7, 2025 | Offer document | SEC |
| RW · Request to withdraw a registration | Oct 7, 2025 | Other filings | SEC |
| S-3ASR · Registration statement | Oct 3, 2025 | Offer document | SEC |
| RW · Request to withdraw a registration | Oct 3, 2025 | Other filings | SEC |
| S-3 · Registration statement | Sep 30, 2025 | Offer document | SEC |
| 8-K/A · Current report, amended | Sep 30, 2025 | Current report | SEC |
| 4 · Change in ownership | Sep 18, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 16, 2025 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Sep 15, 2025 | Meeting notice | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 12, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 12, 2025 | Insider trade | SEC |
| SCHEDULE 13D · Big-stake notice | Sep 12, 2025 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 12, 2025 | Other filings | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 11, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 9, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 9, 2025 | Other filings | SEC |
| 4/A · Change in ownership, amended | Sep 8, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Sep 8, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Sep 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 3, 2025 | Other filings | SEC |
| 8-K · Current report | Sep 2, 2025 | Acquisition or disposal | SEC |
| 8-K · Current report | Aug 12, 2025 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 8, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 7, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 7, 2025 | Results | SEC |
| 8-K · Current report | Jun 30, 2025 | Current report | SEC |
| 424B5 · Prospectus | Jun 30, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Jun 26, 2025 | Offer document | SEC |
| 8-K · Current report | Jun 25, 2025 | Meeting outcome | SEC |
| 8-K · Current report | Jun 23, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 12, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| ARS · Annual report to shareholders | Apr 28, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 22, 2025 | Current report | SEC |
| 8-K · Current report | Apr 8, 2025 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Apr 4, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Apr 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Apr 2, 2025 | Insider trade | SEC |
| 10-K · Annual report | Mar 25, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 25, 2025 | Results | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 5, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 22, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 14, 2025 | Insider trade | SEC |
| 8-K · Current report | Jan 7, 2025 | Results | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 25, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 144 · Notice of proposed sale | Nov 14, 2024 | Other filings | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 14, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Oct 30, 2024 | Quarterly report | SEC |
| 8-K · Current report | Oct 30, 2024 | Results | SEC |
| DEF 14A · Proxy statement | Oct 8, 2024 | Meeting notice | SEC |
| 10-Q · Quarterly report | Aug 14, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 14, 2024 | Results | SEC |
| EFFECT · Notice that a registration is effective | May 23, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | May 20, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | May 15, 2024 | Other filings | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| S-3 · Registration statement | May 9, 2024 | Offer document | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Mar 14, 2024 | Insider trade | SEC |
| 10-K · Annual report | Mar 12, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 12, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 30, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jan 29, 2024 | Big-stake notice | SEC |
| 4/A · Change in ownership, amended | Jan 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 18, 2023 | Insider trade | SEC |
| 8-K · Current report | Dec 15, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Dec 14, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 14, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Nov 17, 2023 | Insider trade | SEC |
| 8-K · Current report | Nov 16, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 14, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 14, 2023 | Results | SEC |
This page holds 200 of 1,002 filings. Open Filings
Cap table
Built by 6ix from CorMedix Inc.’s releases · as of Sep 2, 2025
- Common shares
- 77,944,324
- Fully diluted
- 77,944,324
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 77,944,324 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 77,944,324 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Alan W. Dunton Other companies: Palatin Technologies, Inc. (Director · Since at least Jun 22, 2011); Oragenics Inc. (Director · Since at least Apr 1, 2011); Adams Respiratory Therapeutics Inc (Director · Nov 8, 2006 – Jan 29, 2008 · Past); Gyre Therapeutics, Inc. (Director · Oct 18, 2006 – Aug 14, 2015 · Past); MediciNova, Inc. (Director · May 11, 2006 – Jun 11, 2010 · Past) | Director · Since at least Mar 1, 2019 |
| Bami Bastani Other companies: Aquantia Corp (Director · Nov 2, 2017 – Jun 19, 2019 · Past); Meru Networks Inc (President & CEO, Director · Mar 21, 2012 – Jul 8, 2015 · Past); ANADIGICS Inc (CEO, Director · Apr 27, 2007 – Jul 25, 2008 · Past); TaoWeave, Inc. (Director · Apr 23, 2007 – May 28, 2009 · Past) | Director · Mar 24, 2010 – Jan 14, 2011 · Past |
| Richard Cohen Other companies: Direct Digital Holdings, Inc. (Director · Since at least Feb 15, 2022); Blue Biofuels, Inc. (CFO · Jan 21, 2014 – Jan 21, 2014 · Past); Dominari Holdings Inc. (Chief Financial Officer · Jan 6, 2014 – Jan 6, 2014 · Past); Direct Markets Holdings Corp (Director · Aug 13, 2007 – Jul 2, 2012 · Past) | Chief Financial Officder, Director · Mar 24, 2010 – Mar 20, 2013 · Past |
| Robert W Cook Other companies: Elite Express Holding Inc. (See Remarks · Since at least Aug 20, 2025); MELA Sciences Inc (Chief Financial Officer · Apr 14, 2014 – Feb 3, 2015 · Past); Immune Pharmaceuticals Inc (CFO and Senior VP, Director · Feb 3, 2014 – Feb 3, 2014 · Past) | Chief Financial Officer · Feb 1, 2017 – Sep 30, 2019 · Past |
| Cora M Tellez Other companies: Pacific Premier Bancorp Inc (Director · Oct 3, 2015 – Mar 15, 2022 · Past); HMS Holdings Corp (Director · Jun 30, 2015 – Mar 31, 2021 · Past) | Director · Aug 14, 2015 – May 30, 2017 · Past |
| Joseph Todisco Other companies: Talphera, Inc. (Director · Since at least Oct 14, 2025); Amneal Pharmaceuticals, Inc. (Executive Vice President · May 7, 2019 – May 7, 2022 · Past) | Chief Executive Officer, Director · Since at least Mar 18, 2022 |
| Khoso Baluch Other companies: Longeveron Inc. (Director · Since at least Jun 9, 2023); Processa Pharmaceuticals, Inc. (Member · Since at least Jul 11, 2022) | Chief Executive Officer, Director · Oct 3, 2016 – Jan 11, 2021 · Past |
| Paulo F Costa Other companies: MacroGenics, Inc. (Director · Oct 9, 2013 – May 13, 2021 · Past); Amylin Pharmaceuticals LLC (Director · Jun 9, 2009 – Aug 8, 2012 · Past) | Director · Sep 15, 2020 – May 17, 2023 · Past |
| Susan Blum Other companies: BiomX Inc. (Director · Apr 11, 2024 – Apr 14, 2025 · Past); Melinta Therapeutics Inc (VP of Finance & CAO · Oct 17, 2019 – Oct 17, 2019 · Past) | EVP & Chief Financial Officer · Since at least Aug 29, 2025 |
| Taunia Markvicka Other companies: Statera Biopharma, Inc. (Chief Operating Officer, Director · Sep 28, 2021 – Sep 28, 2021 · Past); Pacira BioSciences, Inc. (SVP, Chief Commercial Officer · Mar 21, 2012 – Mar 17, 2015 · Past) | Director · Apr 4, 2014 – May 15, 2017 · Past |
All 39 people
| Person | Seat |
|---|---|
| Greg Duncan Other companies: Dogwood Therapeutics, Inc. (Chief Executive Officer & Chairman of the Board of Directors · Since at least Oct 19, 2026) | Director · Since at least Nov 4, 2026 |
| Gregory Scott Duncan Other companies: Dogwood Therapeutics, Inc. (CHIEF EXECUTIVE OFFICER, Director · Since at least Dec 16, 2020) | Director · Since at least Nov 2, 2020 |
| James Lefkowitz Other companies: Digital Turbine, Inc. (President · Jun 28, 2007 – Mar 16, 2009 · Past) | Director · Dec 15, 2011 – Dec 15, 2011 · Past |
| Joe Todisco Other companies: Talphera, Inc. (Director · Oct 21, 2025 – Nov 4, 2026 · Past) | Chief Executive Officer and Chairman · Since at least Mar 5, 2026 |
| Judith R Abrams Other companies: Editas Medicine, Inc. (Chief Medical Officer · Oct 28, 2019 – Oct 28, 2019 · Past) | Chief Medical Officer · Feb 1, 2017 – Feb 1, 2017 · Past |
| Matthew T David Other companies: Actinium Pharmaceuticals, Inc. (Delaware) (Chief Financial Officer · Since at least Oct 14, 2026) | Chief Financial Officer · May 11, 2020 – Jan 10, 2025 · Past |
| Randy Milby Other companies: Canton Strategic Holdings, Inc. (CEO, Director · Jan 11, 2022 – Jan 13, 2025 · Past) | Chief Executive Officer, Director · May 14, 2012 – Aug 10, 2016 · Past |
| Robert Stewart Other companies: Amneal Pharmaceuticals, Inc. (President and CEO, Director · May 4, 2018 – May 7, 2019 · Past) | Director · Since at least Apr 13, 2023 |
| Steven W Lefkowitz Other companies: Franklin Credit Management Corp. (Director · Oct 12, 2012 – May 24, 2013 · Past) | Director · Since at least Aug 11, 2011 |
| Antony Pfaffle | Chief Scientific Officer · Mar 24, 2010 – Feb 7, 2017 · Past |
| Beth Zelnick Kaufman | EVP, Chief Legal and Compliance Officer, and Corporate Secretary · Since at least Sep 2, 2025 |
| Elizabeth Hurlburt | Chief Operating Officer · Since at least Mar 19, 2018 |
| Erin Mistry | EVP, Chief Commercial Officer · Jan 14, 2023 – Jan 10, 2025 · Past |
| Gary A Gelbfish | Director · Mar 24, 2010 – Jan 10, 2019 · Past |
| Harry O'Grady | Chief Financial Officer · Jul 21, 2014 – Jul 21, 2014 · Past |
| Janet D. Dillione | Director · Since at least Nov 14, 2017 |
| John L Armstrong Jr | Exec VP of Tech Operations · Mar 1, 2017 – Jan 11, 2021 · Past |
| Kaufman Beth Zelnick | Chief Legal Officer · Since at least Dec 12, 2023 |
| Liz Hurlburt | EVP, Chief Operating & Commercial Officer · Since at least Sep 2, 2025 |
| Mark A Klausner | Chief Medical Officer · Mar 1, 2011 – Mar 1, 2011 · Past |
| Mark T Houser | Chief Medical Officer · Mar 24, 2010 – Nov 26, 2010 · Past |
| Matthew Duffy | Director · Nov 21, 2011 – Jun 3, 2016 · Past |
| Michael David Seckler | Chief Commercial Officer · Since at least Jan 8, 2026 |
| Mike Seckler | EVP & Chief Commercial Officer · Since at least Jan 8, 2026 |
| Myron Kaplan | Lead Independent Director · Since at least Apr 27, 2016 |
| Phoebe Mounts | General Counsel · May 1, 2019 – Jan 14, 2023 · Past |
| Steven Lefkowitz | Director · Since at least Nov 4, 2026 |
| Thomas Nusbickel | EVP, Chief Commercial Officer · May 13, 2021 – Feb 18, 2022 · Past |
| Timothy M Hofer | Director · Mar 24, 2010 – Jan 6, 2012 · Past |
Log in to ask 6ix AI your own questions about CorMedix Inc.